SAN DIEGO – At a Calbio session, Cambell Alliance, the business consulting segment of Inventiv Health Inc., presented its survey of business development professionals...In addition to the forward-looking examination of dealmaking expectations, a panel gave their experiences in the ever-changing business development

Kala Pharmaceuticals Inc., of Waltham, Mass., appointed Charles McDermott executive vice president of business development

The intention is to move forward and get that triple combination into development quickly," said Lyn Baranowski, Pearl's vice president of business development

Hans-Peter Grau, vice president for business development and key account management for Asia, contract manufacturing biopharmaceuticals at Boehringer Ingelheim Biopharmaceuticals GmbH, reminded the audience of the rapid transformation the agency has been facing

Kevin Eastwood, senior vice president of business development

Some of our investors are interested in going the distance, and we have some business development opportunities

said Rosamond Deegan, vice president of business development for King of Prussia, Pa.-based Trevena

Mathieu Boudreau, director of business development at Montreal-based Pharmascience, said Redx would be able to continue work on the CSR-1R inhibitor while Pharmascience concentrates on a tyrosine kinase inhibitor program and getting the lead program, AEP40826, an apoptosis inhibitor, into Phase I/IIb studies

The Jazz deal that we did a couple of months ago really brought a lot of attention to us, and we've had a good set of inquiries on the business development front from companies we've never heard from previously

Oramed Pharmaceuticals Inc., of Jerusalem, named Joshua Hexter chief operating officer and vice president of business development

Vancouver, British Columbia $0.75 viDA completed a second tranche, equity financing of $750,000 from the Business Development Bank of Canada's venture capital arm, bringing total gross proceeds of the seed round to about $3.646M 4/25/13 Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International

co-head of business development and mergers, John McDonald, was "not a big fan" of the option deal, which he said can have terms that are "tougher on the smaller company," particularly because it leaves the smaller partner vulnerable to the stigma of an un-exercised option, making it harder to find a new partner to replace the one that backed out, even if the decision was not based on failure of the compound, but for strategic reasons on the part of the larger company...asked George Golumbeski

co-head of business development and mergers, John McDonald, was "not a big fan" of the option deal, which he said can have terms that are "tougher on the smaller company," particularly because it leaves the smaller partner vulnerable to the stigma of an un-exercised option, making it harder to find a new partner to replace the one that backed out, even if the decision was not based on failure of the compound, but for strategic reasons on the part of the larger company...asked George Golumbeski

The director of business development at a Japanese specialty pharma first contacted Avaxia at BIO 2012, and the companies talked often in the ensuing months...Fox greeted a long-time acquaintance who's now director of business development for a European biopharma with a significant U.S

viDA Therapeutics Inc., of Vancouver, British Columbia, completed a second tranche, equity financing of $750,000 from the business Development Bank of Canada's venture capital arm (BDC Venture Capital), bringing total gross proceeds of the seed round to about $3.646 million

Robert Speziale, vice president of business development for Invetech Pty

At the same time, the agreement exemplifies changes to AstraZeneca's business development and partnering strategy, following the announcement of the reshaping of its R&D in March. (See BioWorld International, March 20, 2013.) Under the agreement, AstraZeneca is getting access to an early stage, first-in-class kinase target discovered by Horizon, which it is hoped will overcome resistance to chemotherapy that is induced by KRAS mutations in tumors...to develop and commercialize an Accurin

to a $180.5 million collaboration involving its Accurin platform. (See BioWorld Today, Jan. 9, 2013, and April 4, 2013.) That much activity "tells you everything you need to know about the promise of the technology," said BIND CEO Scott Minick, though he also gave props to Dan Koerwer, the firm's head of marketing and business development, who he said deserves a "shrine in the BD hall of fame